Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma
/in Dendritic Cells, International Publications, Malignant Lymphoma /von 2022-02-15 / Leuk Lymphoma 2022 Jul;63(7):1733-1737Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-02-04 / Curr Oncol 2022 Feb;29(2):881-891
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution